Shamburg News · 8-K filed Nov 16, 2026, 7:47 PM EST
NeOnc Technologies Reports Additional NEO100 Phase 2a Response, Objective Response Rate at 12.5%
NTHI · NEONC TECHNOLOGIES HOLDINGS, INC.
- Other event
- Reg FD disclosure
- Materiality: medium
NeOnc Technologies Holdings, Inc. furnished investor presentation materials under Item 7.01 that confirm an additional response in the NEO100 Phase 2a study. The Company reports a total of 3 responses among 24 patients, increasing the objective response rate from 8.3% to 12.5% as assessed using RANO 2.0 criteria. The presentation is attached as Exhibit 99.1 and is dated November 16, 2026.
Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001829126-26-012532.
Written from the filing by Shamburg Markets. Figures are as reported by the company.